Scarica l'app Stockscreener
52.13
0.04%
0.02
Dopo l'orario di chiusura:
53.00
0.87
+1.67%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$52.11
Aprire:
$51.8
Volume 24 ore:
1.02M
Relative Volume:
0.83
Capitalizzazione di mercato:
$4.13B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-8.7761
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
+16.52%
1M Prestazione:
+7.29%
6M Prestazione:
+13.62%
1 anno Prestazione:
+59.47%
Intervallo 1D:
$50.67
$52.40
Intervallo di 1 settimana:
$44.15
$52.70
Portata 52W:
$29.02
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
52.13 | 4.13B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
What institutional investors are buying PTC Therapeutics Inc. stockAchieve rapid wealth accumulation through smart investing - jammulinksnews.com
Is PTC Therapeutics Inc. a good long term investmentCapitalize on momentum-driven opportunities - jammulinksnews.com
William Blair Lowers Earnings Estimates for PTC Therapeutics - MarketBeat
Should I hold or sell PTC Therapeutics Inc. stock in 2025Get ahead with breakthrough trading ideas - jammulinksnews.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by XTX Topco Ltd - MarketBeat
What drives PTC Therapeutics Inc. stock priceInvest confidently with professional market insights - jammulinksnews.com
What are the latest earnings results for PTC Therapeutics Inc.Exponentially increasing returns - jammulinksnews.com
How does PTC Therapeutics Inc. compare to its industry peersAchieve breakthrough financial results - jammulinksnews.com
Is it the right time to buy PTC Therapeutics Inc. stockTake advantage of unprecedented market momentum - jammulinksnews.com
What makes PTC Therapeutics Inc. stock price move sharplyIdentify winners with top-tier analysis - jammulinksnews.com
What is the risk reward ratio of investing in PTC Therapeutics Inc. stockInvest with confidence backed by data - jammulinksnews.com
Why is PTC Therapeutics Inc. stock attracting strong analyst attentionExceptional profit velocity - jammulinksnews.com
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up After Analyst Upgrade - MarketBeat
How does PTC Therapeutics Inc. generate profit in a changing economyBuild a diversified portfolio for risk management - jammulinksnews.com
What are PTC Therapeutics Inc. company’s key revenue driversGet expert insights on market-moving stocks - jammulinksnews.com
Bank of America Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Stock Price Expected to Rise, UBS Group Analyst Says - MarketBeat
Bayforest Capital Ltd Takes $415,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Q3 Earnings Estimate for PTCT Issued By William Blair - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $46.00 at Barclays - MarketBeat
Truist Financial Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price - MarketBeat
PTC Therapeutics (PTCT) to Release Quarterly Earnings on Thursday - MarketBeat
Is PTC Therapeutics Inc. a growth stock or a value stockChart Pattern Tips For Beginners - jammulinksnews.com
Q3 EPS Forecast for PTC Therapeutics Decreased by Analyst - MarketBeat
PTC Therapeutics: Uncertainty Abounds Ahead Of Q2 EarningsI'm Upgrading To 'Hold' - Seeking Alpha
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
PTC Therapeutics shares rise 1.57% premarket after expanding collaboration with NVIDIA for AI development. - AInvest
Y Intercept Hong Kong Ltd Sells 6,043 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Using data models to predict PTC Therapeutics Inc. stock movementSwing Entry Insight With Forecast Accuracy - Newser
Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval - BioPharma Dive
Wells Fargo & Company Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $120.00 at Cantor Fitzgerald - MarketBeat
PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains? - Nasdaq
A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $46 to $120 - 富途牛牛
Orsini Selected as Specialty Pharmacy Partner for PTC Therapeutics' SEPHIENCE™ (sepiapterin) - Yahoo Finance
36,246 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Neo Ivy Capital Management - MarketBeat
Price Reversal in PTC Therapeutics Inc. Traders Watch CloselyBuy Low Sell High Stock Watch Strategy in Focus - beatles.ru
Universal Beteiligungs und Servicegesellschaft mbH Purchases 36,365 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
AI Tools Suggest PTC Therapeutics Inc. May Outperform This WeekSecure Return Focused Investment Plan Released - metal.it
PTC Therapeutics Inc. Breakout Confirmed by Volume MetricsBreakout Momentum Picks With Protection Outlined - metal.it
PTC To Challenge BioMarin In PKU With Oral Sephience - insights.citeline.com
PTC Therapeutics (NASDAQ:PTCT) Shareholders Are Still up 36% Over 1 Year Despite Pulling Back 7.4% in the Past Week - 富途牛牛
PTCT’s Future: A Game Changer? - StocksToTrade
Why Is PTC Therapeutics Stock Trading Higher Today?PTC Therapeutics (NASDAQ:PTCT) - Benzinga
PTC Therapeutics stock price target raised to $120 from $112 at Cantor Fitzgerald - Investing.com
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):